Juvenile Arthritis News and Research

RSS

Children with JIA face increase risk of developing cancer

Children with juvenile idiopathic arthritis have a two to threefold increased risk of developing cancer compared to similarly-aged children without JIA, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. The same study also reported no cases of cancer in children with JIA who were exposed to anti-TNF therapy.

9 Nov 2010

Thirteen myths about arthritis and rheumatic disease

A diagnosis of arthritis or another rheumatic disease can cause someone to feel anxious and even a little overwhelmed. Being a knowledgeable and empowered patient can help alleviate some of those feelings, and being able to navigate through the many misconceptions about arthritis and rheumatic diseases is vitally important.

8 Nov 2010

ACTEMRA reduces signs, symptoms in patients with rheumatoid arthritis

Genentech, Inc., a member of the Roche Group today announced updated data from a Phase III study (ROSE) that showed rheumatoid arthritis (RA) patients receiving ACTEMRA (tocilizumab) experienced a rapid, measured response as early as one week after beginning ACTEMRA, and improvement in disease activity within four weeks.

8 Nov 2010

Etanercept plus MTX improves height, weight, and BMI in children with juvenile idiopathic arthritis

Researchers from the Cincinnati Children's Hospital Medical Center observed a statistically significant increase in mean height, weight, and body mass index (BMI) percentiles in patients with juvenile idiopathic arthritis (JIA) who were treated with etanercept or etanercept plus methotrexate (MTX). JIA patients treated with MTX alone did not display an increase in growth percentiles.

4 Nov 2010

Arthritis Foundation urges FDA to expeditiously create regulatory pathway for biosimilars

Arthritis Foundation patient advocate, Jan Wyatt, PhD, will provide oral testimony on behalf of the approximately 4 million Americans with inflammatory arthritis at a Food and Drug Administration (FDA) hearing today. The hearing will focus on issues and challenges associated with an approval pathway for biologic products that are highly similar "biosimilar" or interchangeable with FDA-licensed products.

3 Nov 2010

Baylor Institute of Immunology Research receives nearly $35M as grants in 2009

Even in an economy that's proved devastating to charitable giving and government grants, the Baylor Institute of Immunology Research (BIIR), a component of Baylor Research Institute (BRI), has managed to buck the trend: BIIR received grants totaling nearly $35 million in 2009.

10 Jun 2010

Gene expression differences could bring better classification and treatment of juvenile arthritis

Scientists have discovered gene expression differences that could lead to better ways to classify, predict outcome, and treat juvenile idiopathic arthritis (JIA). Eventually such findings could enable doctors to target more aggressive treatment to children at risk of more severe arthritis, while those likely to have milder disease could be spared the stronger treatments that carry a greater risk of side effects. The researchers were supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health.

29 Jun 2009

As many as 4,600 Australian children affected by juvenile arthritis

Experts say as many as 4,600 Australian children under the age of 16 suffer from juvenile arthritis.

29 Oct 2008

Latona acquires patent rights and orphan drug status to drug compound for rheumatoid arthritis

Latona Life Sciences Inc. announced today that it has entered into two agreements for the acquisition of patent rights and orphan drug status to a novel late-stage drug, trademarked "Oralgam," for the treatment of Juvenile and Adult Rheumatoid Arthritis.

24 Apr 2008

Growing burden of arthritis in the U.S.

Arthritis is the most common cause of disability in the United States. Over the next 25 years as the Baby Boom generation continues to age, the toll of this disease will escalate.

3 Jan 2008

Key arthritis legislation could positively impact nation's most common cause of disability

On Wednesday, September 19, the American College of Rheumatology and the Arthritis Foundation will jointly brief members of Congress and their staffs about the devastating effects of arthritis and related rheumatic diseases.

13 Sep 2007

Researchers develop criteria to detect bone mass deficiencies in children with chronic diseases

Pediatricians now have a practical tool to help determine whether children with chronic diseases like Crohn's, juvenile arthritis and anorexia nervosa or those undergoing cancer treatment are at increased risk for bone mass deficiencies, fracture or osteoporosis as they get older, according to a new study whose lead author is a researcher at Cincinnati Children's Hospital Medical Center.

8 Jun 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

New findings have implications for chronic use of COX-2 Inhibitors in pre-menopausal women

Heart disease is less pronounced in women than in men as humans age, but this difference narrows after menopause. Some studies have shown that estrogen slows heart disease in mouse models, but the mechanism is largely unknown.

18 Nov 2004